Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

SVB Leerink 11th Annual Global Healthcare ConferenceFebruary 17, 20221:40 p.m. ET – fireside chat presentation

Cowen 42nd Annual Health Care ConferenceMarch 7, 202210:30 a.m. ET – leukemias panel discussion

Oppenheimer 32nd Annual Healthcare ConferenceMarch 16, 202210:00 a.m. ET – presentation

A simultaneous webcast of the presentations will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.

About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:Greg MannNkarta, Inc.[email protected]

You May Also Be Interested In

• Membrane Solutions Launches New Outdoor Water Filtration Solutions at Outdoor Retailer 2026
• AANA Launches Anesthesia Answers, a Patient Education Resource Built by CRNAs/Nurse Anesthesiologists
• Monero Price Prediction Eyes $500 as DEX Volume Hits $700M and Pepeto Presale Pulls In $10.7M